Drug intelligence / Profile preview

CoVEVax

Development stage: Preclinical
Lead developer: Ciloa
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intranasal, Inhalation

Overview

CoVEVax is a preclinical-stage pan-coronavirus vaccine candidate developed by Ciloa. It utilizes a proprietary small extracellular vesicle (sEV) platform where the SARS-CoV-2 Spike protein is fused to a "Pilot Peptide" and displayed on the surface of the sEVs. This approach is designed to induce a robust antiviral immune response against SARS-CoV-2 and potentially other coronaviruses by presenting the antigen in a natural, membrane-bound conformation to enhance immunogenicity.

Brand names: CoVEVax
Other names: SARS-CoV-2 vaccineSARS-CoV2 vaccineSARS-CoV 2 vaccinepan-coronavirus vaccine

Targets

SARS-CoV-2 spike glycoprotein (displayed on extracellular vesicles)BCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on CoVEVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoVEVax.

Explore the full profile